Aventis collaboration expires Peptor
Aventis has made planning permission for DiaPep277 for type 1 diabetes to DeveloGen and ended the cooperation agreement for connection with DeveloGen. At this point, Aventis has determined the development project no longer meets the criteria of his priorities for the progression of corporate business, and decided to concentrate on other connections in its diabetes pipeline. The details were not disclosed. About Aventis Aventis to treat and prevent disease through the discovery and development of new drugs and vaccines.In 2003, Aventis generated sales of 16.79 billion, 2.86 billion dollars invested in research and development and employs approximately 69,000 people in its core business. Aventis corporate headquarters in Strasbourg, France.Statements in this press release
contains projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure or other financial items, plans and objectives for future operations, products or services, future economic performance or assumptions underlying or relating to these statements are forward-looking statements involve risks and uncertainties. Actual results may differ materially depending on factors such as timing and effects of regulatory actions, results of clinical trials, the success of the company and on the development of market acceptance of new products, the result of litigation, important, and the effectiveness of patent protection.More current information on risks and uncertainties, the current annual report on Form 20-F of Aventis on file with theSecurities and Exchange Commission and the annual report Rfrence document in the archives of the commission of the elaborations Exchange in France.Under Article 7 of Regulation No COB 2002-04 of this press release, the Autorité des marchés financiers before its release has been sent.